Business Context and Reporting Period
This Form 8-K was filed by Cortexyme, Inc. (not Quince Therapeutics, Inc.) on February 9, 2021. The report details significant changes to the company's executive leadership structure and associated compensation arrangements effective February 10, 2021.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel appointments and equity grants.
Material Changes
- Executive Role Transition: Chris Lowe was appointed as Chief Operating Officer (COO) in addition to his existing role as Chief Financial Officer (CFO).
- Principal Accounting Officer Change: Ted Monohon was appointed as the new Chief Accounting Officer and "principal accounting officer," succeeding Chris Lowe in that specific function.
- Compensation Adjustments:
- Chris Lowe's annual base salary increased to $450,000.
- Chris Lowe's annual discretionary performance bonus increased to 45% of his base salary.
- Chris Lowe received a stock option to purchase 40,000 shares of common stock.
- Ted Monohon received a stock option to purchase 20,000 shares of common stock.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. It notes that neither executive has family relationships with other directors or officers and that no transactions requiring disclosure under Item 404(a) of Regulation S-K exist.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price for the 40,000 options granted to Chris Lowe and the 20,000 options granted to Ted Monohon.
- Confirm the effective date of the salary increase for Chris Lowe (February 10, 2021).
- Review the company's 2019 Equity Incentive Plan to understand the terms governing these grants.
- Note the correction of the company name: The filing is for Cortexyme, Inc. (CRTX), not Quince Therapeutics, Inc.